Vorapaxar in Acute Limb Ischemia

Original Title: Acute Limb Ischemia and Outcomes With Vorapaxar in Patients with Peripheral Artery Disease: Results From TRA2°P-TIMI 50. Reference: Marc P. Bonaca et al. Circulation. 2016 Mar 8;133(10):997-1005.

 

Patients with peripheral artery disease have a high risk of acute limb ischemia, an event that may result in the loss of the affected limb.

This study addresses the causes, sequelae and predictors of acute limb ischemia and test the hypothesis that PAR-1 antagonism with vorapaxar reduce its incidence.

The TRA2°P-TIMI 50 was a randomized, double blind, placebo controlled trial that tested Vorapaxar in stable patients, including 3787 with a history of symptomatic peripheral arterial disease. Acute limb ischemia was pre-specified in the study.

A total of 150 acute limb ischemia events in 108 patients occurred during follow up(3.9% to 3 years, 1.3% annualized).

In patients with symptomatic peripheral artery disease, smoking, prior revascularization and ankle-brachial index were predictors of acute limb ischemia.

Most of the acute ischemia events were due to femoropopliteal surgical graft thrombosis (56%), followed by native vessel in situ thrombosis (27%).

Stent thrombosis and thromboembolism caused acute limb ischemia in 13% and 5% respectively. Amputation occurred in 17.6% of acute limb ischemia patients. Vorapaxar reduced the chance of acute ischemia by 41% (HR 0.58, 95% CI 0.39 to 0.86; p=0.006) and this efficacy was consistent across acute ischemia etiology.

Conclusion
In selected patients with symptomatic peripheral artery disease with no atrial fibrillation, the rate of acute limb ischemia is 1.3% per year and is more often caused by acute thrombosis of a surgical bypass graft and in situ thrombosis. Vorapaxar reduces acute limb ischemia across all etiologies.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...